Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer.

ABSTRACT: Prostate cancer (PCa) is a hormone driven cancer, characterised by defects in androgen receptor signalling which drive the disease process. As such, androgen targeted therapies have been the mainstay for PCa treatment for over 70 years. High-risk PCa presents unique therapeutic challenges, namely in minimising the primary tumour, and eliminating any undetected micro metastases. Trials of neoadjuvant androgen deprivation therapy aim to address these challenges. Patients typically respond well to neoadjuvant treatment, showing regression of the primary tumour and negative surgical margins at the time of resection, however the majority of patients relapse and progress to metastatic disease. The mechanisms affording this resistance are largely unknown. This commentary attempts to explore theor

SUBMITTER: Pechlivanis M 

PROVIDER: S-EPMC8750084 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature